Mountain Crest Acquisition Corp. V MCAG
- Market cap
- $36.2M
- P/E
- 0.0×
Follow MCAG
Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 9.71 | 9.69 |
Analyst estimates 2023–2025 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 9.82 | 10.45 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | 0 | 0 |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | 0 | — | — | — | 0 | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.02) | 0.00 |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.02) | (0.02) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.02) | (0.02) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 7.47 | 1.96 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 9 | 9 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | 0 | 0 |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | 0 | 0 |
FCF
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | 0 | 0 |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 67 | 17 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | (0.43%) | 0.01% |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.01% |
ROE
|
|||
Mountain Crest Acquisition Corp. V peers in Shell Companies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AFJK Aimei Health Technology Co., Ltd. | $38.6M | 60.0× | Compare |
| WINV WinVest Acquisition Corp. | $39.2M | 0.0× | Compare |
| NOEM CO2 Energy Transition Corp. | $39.4M | 28.7× | Compare |
| BAYA Bayview Acquisition Corp. | $33.3M | — | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IPEX Inflection Point Acquisition Corp. V | $33.2M | — | Compare |
| FSHP Flag Ship Acquisition Corporation | $39.8M | — | Compare |
| LCCC Lakeshore Acquisition III Corp. | $40.5M | — | Compare |
| IGTA Inception Growth Acquisition Limited | $41.6M | 0.4× | Compare |
Mountain Crest Acquisition Corp. V (MCAG) key facts
- Mountain Crest Acquisition Corp. V (MCAG) is a Shell Companies company in the Financial sector.
- Net income was $4,500.00, or $0.00 per share (basic), a net margin of 0.00%.
- As of September 24, 2026, MCAG traded at $13.27, a market capitalization of $36.2 million.
- Return on equity was 0.01% and debt-to-equity 0.04.
Mountain Crest Acquisition Corp. V (MCAG) Latest News
18 Sep
Mountain Crest Acquisition Corp. V received a deficiency notification from Nasdaq for delayed filing of quarterly reports, but has made progress towards regaining compliance. The delayed filing of quarterly reports may moderately influence the company's financial performance and compliance status.
29 Aug
Mountain Crest Acquisition Corp. V and CUBEBIO announce a definitive business combination agreement for CUBEBIO to become a publicly listed company on Nasdaq. The business combination agreement with CUBEBIO has the potential to significantly impact Mountain Crest Acquisition Corp. V's future and market performance.
24 Jul
Mountain Crest Acquisition Corp. V received a deficiency notification from Nasdaq due to delayed filing of annual and quarterly reports. The delayed filing of reports may moderately impact the company's financial performance and compliance with Nasdaq listing rules.
2 May
CUBEBIO Co., Ltd. and Mountain Crest Acquisition Corp. V entered into a non-binding term sheet for a proposed business combination. The potential business combination with CUBEBIO has the potential to significantly impact Mountain Crest Acquisition Corp. V's future and market performance.
25 Oct
Mountain Crest Acquisition Corp. V transfers listing to Nasdaq Capital Market effective October 27, 2023. The transfer of listing may moderately influence the company's financial performance and competitive positioning.
30 May
AUM Biosciences doses first patient in Phase 2 clinical trial of AUM001 in metastatic colorectal cancer. The Phase 2 trial of AUM001 in metastatic colorectal cancer has the potential to significantly impact Mountain Crest Acquisition Corp. V's future and market performance.